{
    "id": "e8f3396b-251b-4218-9dd8-4ad0a0f8f2a2",
    "indications": "bupropion hydrochloride extended-release ( sr ) tablets indicated treatment major depressive disorder ( mdd ) , defined diagnostic statistical manual ( dsm ) . efficacy bupropion treatment major depressive episode established two 4-week controlled inpatient trials one 6-week controlled outpatient trial adult subjects mdd [ ( 14 ) ] . efficacy bupropion hydrochloride extended-release ( sr ) tablets maintaining antidepressant response 44 weeks following 8 weeks acute treatment demonstrated placebo-controlled trial [ ( 14 ) ] .",
    "contraindications": "• starting dose : 150 mg/day . ( 2.1 ) • general : increase dose gradually reduce seizure risk . ( 2.1 , 5.3 ) • 3 days , may increase dose 300 mg/day , given 150 mg twice daily interval least 8 hours . ( 2.1 ) • usual target dose : 300 mg/day 150 mg twice daily . ( 2.1 ) • maximum dose : 400 mg/day , given 200 mg twice daily , patients responding 300 mg/day . ( 2.1 ) • periodically reassess dose need maintenance treatment . ( 2.1 ) • moderate severe hepatic impairment : 100 mg daily 150 mg every day . ( 2.2 , 8.7 ) • mild hepatic impairment : consider reducing dose and/or frequency dosing . ( 2.2 , 8.7 ) • renal impairment : consider reducing dose and/or frequency . ( 2.3 , 8.6 )",
    "warningsAndPrecautions": "bupropion hydrochloride extended-release tablets usp ( sr ) , 100 mg bupropion hydrochloride , usp blue , round , biconvex , film-coated tablets debossed “ ” one side “ 522 ” . bottles 60 ndc # 43547-288-06 bottles 90 ndc # 43547-288-09 bottles 100 ndc # 43547-288-10 bottles 500 ndc # 43547-288-50 bupropion hydrochloride , usp extended-release tablets usp ( sr ) , 150 mg bupropion hydrochloride , usp purple , round , biconvex , film-coated tablets debossed “ ” one side “ 525 ” . bottles 60 ndc # 43547-289-06 bottles 90 ndc # 43547-289-09 bottles 100 ndc # 43547-289-10 bottles 250 ndc # 43547-289-25 bottles 500 ndc # 43547-289-50 bupropion hydrochloride extended-release tablets usp ( sr ) , 200 mg bupropion hydrochloride , usp pink , round , biconvex , film-coated tablets debossed “ ” one side “ 527 ” . bottles 60 ndc # 43547-290-06 bottles 90 ndc # 43547-290-09 bottles 100 ndc # 43547-290-10 bottles 500 ndc # 43547-290-50 store room temperature , 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . protect light moisture .",
    "adverseReactions": "•bupropion hydrochloride extended-release ( sr ) tablets contraindicated patients seizure disorder . •bupropion hydrochloride extended-release ( sr ) tablets contraindicated patients current prior diagnosis bulimia anorexia nervosa higher incidence seizures observed patients treated immediate-release formulation bupropion [ ( 5.3 ) ] . •bupropion hydrochloride extended-release ( sr ) tablets contraindicated patients undergoing abrupt discontinuation alcohol , benzodiazepines , barbiturates , antiepileptic drugs [ ( 5.3 ) , ( 7.3 ) ] . •the maois ( intended treat psychiatric disorders ) concomitantly bupropion hydrochloride extended-release ( sr ) tablets within 14 days discontinuing treatment bupropion hydrochloride extended-release ( sr ) tablets contraindicated . increased risk hypertensive bupropion hydrochloride extended-release ( sr ) tablets used concomitantly maois . bupropion hydrochloride extended-release ( sr ) tablets within 14 days discontinuing treatment maoi also contraindicated . starting bupropion hydrochloride extended-release ( sr ) tablets patient treated reversible maois linezolid intravenous methylene blue contraindicated [ ( 2.4 , 2.5 ) , ( 5.4 ) , ( 7.6 ) ] . •bupropion hydrochloride extended-release ( sr ) tablets contraindicated patients known hypersensitivity bupropion ingredients bupropion hydrochloride extended-release ( sr ) tablets . anaphylactoid/anaphylactic stevens-johnson syndrome reported [ ( 5.8 ) ] .",
    "ingredients": [
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O"
        },
        {
            "name": "CYSTEINE HYDROCHLORIDE",
            "code": "ZT934N0X4W"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "organization": "Solco Healthcare US LLC",
    "name": "bupropion hydrochloride",
    "effectiveTime": "20240628",
    "indications_original": "Bupropion hydrochloride extended-release (SR) tablets are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM).\n                  The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD [see Clinical Studies (14)].\n                  The efficacy of bupropion hydrochloride extended-release (SR) tablets in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial [see Clinical Studies (14)].",
    "contraindications_original": "• Starting dose: 150 mg/day. ( 2.1 ) • General: Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) • After 3 days, may increase the dose to 300 mg/day, given as 150 mg twice daily at an interval of at least 8 hours. ( 2.1 ) • Usual target dose: 300 mg/day as 150 mg twice daily. ( 2.1 ) • Maximum dose: 400 mg/day, given as 200 mg twice daily, for patients not responding to 300 mg/day. ( 2.1 ) • Periodically reassess the dose and need for maintenance treatment. ( 2.1 ) • Moderate to severe hepatic impairment: 100 mg daily or 150 mg every other day. ( 2.2 , 8.7 ) • Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. ( 2.2 , 8.7 ) • Renal impairment: Consider reducing the dose and/or frequency. ( 2.3 , 8.6 )",
    "warningsAndPrecautions_original": "Bupropion hydrochloride extended-release tablets USP (SR), 100 mg of bupropion hydrochloride, USP are blue, round, biconvex, film-coated tablets debossed with “S” on one side and “522” on the other.\n                  \n                     \n                     \n                     \n                        \n                           \n                              Bottles of 60\n                           \n                           \n                              NDC # 43547-288-06\n                           \n                        \n                        \n                           \n                              Bottles of 90\n                           \n                           \n                              NDC # 43547-288-09\n                           \n                        \n                        \n                           \n                              Bottles of 100\n                           \n                           \n                              NDC # 43547-288-10\n                           \n                        \n                        \n                           \n                              Bottles of 500\n                           \n                           \n                              NDC # 43547-288-50\n                           \n                        \n                     \n                  \n                  Bupropion hydrochloride, USP extended-release tablets USP (SR), 150 mg of bupropion hydrochloride, USP are purple, round, biconvex, film-coated tablets debossed with “S” on one side and “525” on the other.\n                  \n                     \n                     \n                     \n                        \n                           \n                              Bottles of 60\n                           \n                           \n                              NDC # 43547-289-06\n                           \n                        \n                        \n                           \n                              Bottles of 90\n                           \n                           \n                              NDC # 43547-289-09\n                           \n                        \n                        \n                           \n                              Bottles of 100\n                           \n                           \n                              NDC # 43547-289-10\n                           \n                        \n                        \n                           \n                              Bottles of 250\n                           \n                           \n                              NDC # 43547-289-25\n                           \n                        \n                        \n                           \n                              Bottles of 500\n                           \n                           \n                              NDC # 43547-289-50\n                           \n                        \n                     \n                  \n                  Bupropion hydrochloride extended-release tablets USP (SR), 200 mg of bupropion hydrochloride, USP are pink, round, biconvex, film-coated tablets debossed with “S” on one side and “527” on the other.\n                  \n                     \n                     \n                     \n                        \n                           \n                              Bottles of 60\n                           \n                           \n                              NDC # 43547-290-06\n                           \n                        \n                        \n                           \n                              Bottles of 90\n                           \n                           \n                              NDC # 43547-290-09\n                           \n                        \n                        \n                           \n                              Bottles of 100\n                           \n                           \n                              NDC # 43547-290-10\n                           \n                        \n                        \n                           \n                              Bottles of 500\n                           \n                           \n                              NDC # 43547-290-50\n                           \n                        \n                     \n                  \n                  Store at room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from light and moisture.",
    "adverseReactions_original": "•Bupropion hydrochloride extended-release (SR) tablets are contraindicated in patients with a seizure disorder.\n                     \n                        •Bupropion hydrochloride extended-release (SR) tablets are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with the immediate-release formulation of bupropion [see Warnings and Precautions (5.3)].\n                     \n                        •Bupropion hydrochloride extended-release (SR) tablets are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3),  Drug Interactions (7.3)].\n                     \n                        •The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release (SR) tablets or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release (SR) tablets is contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release (SR) tablets are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release (SR) tablets within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release (SR) tablets in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration (2.4, 2.5), \n                        \n                           Warnings and Precautions (5.4)\n                        \n                        , Drug Interactions (7.6)].\n                     \n                     \n                        •Bupropion hydrochloride extended-release (SR) tablets are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release (SR) tablets. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [see Warnings and Precautions (5.8)]."
}